Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1455469
This article is part of the Research Topic Community Series in Adenosine Pathways in Cancer Immunity and Immunotherapy: Volume II View all 4 articles

The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer

Provisionally accepted
Carla F. Gardani Carla F. Gardani 1Fernando M. Diz Fernando M. Diz 1,2Luisa B. Donde Luisa B. Donde 1Liliana Rockenbach Liliana Rockenbach 1Stefan Laufer Stefan Laufer 3Fernanda B. Morrone Fernanda B. Morrone 1,3*
  • 1 Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
  • 2 Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
  • 3 University of Tübingen, Tübingen, Baden-Württemberg, Germany

The final, formatted version of the article will be published soon.

    Purines and pyrimidines are signaling molecules in the tumor microenvironment that affect cancer immunity. The purinergic signaling pathways have been shown to play an important role in the development and progression of cancer. CD39 and CD73 are ectonucleotidases responsible for breaking down ATP or ADP into adenosine, which regulates immunosuppression in various types of cancer. These enzymes have been studied as a potential therapeutic target in immunotherapy, and recent research suggests a correlation between ectonucleotidases and clinical outcomes in cancer.Prostate cancer is the most diagnosed cancer in men, after non-melanoma skin tumors, and is the second leading cause of death in men in the world. Despite having long survival periods, patients often receive excessive or insufficient treatment. Within this complex landscape, the adenosine/CD73 pathway plays a crucial role. Therefore, this review aims to highlight new findings on the potential role of purinergic signaling in cancer treatment and emphasizes the importance of anti-CD73 as a pharmacological strategy for prostate cancer therapy.

    Keywords: adenosine1, CD732, CD393, ectonucleotidases4, purinergic system5, prostate cancer6

    Received: 26 Jun 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Gardani, Diz, Donde, Rockenbach, Laufer and Morrone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Fernanda B. Morrone, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.